PNEUMOCOCCAL CONJUGATE VACCINE SCHEDULES SHAPE SEROTYPE-SPECIFIC MEMORY B-CELL RESPONSES
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Reduced-dose pneumococcal conjugate vaccine (PCV) schedules (‘1+1’; one primary and one booster) are now endorsed by the World Health Organisation under specific circumstances. Serotype-specific memory B cells (B MEM ) are a marker of long-term protection but data from infant reduced-dose trials remain limited. As part of a randomised controlled trial in Vietnamese infants, we characterised serotype-specific B MEM responses in randomised subsets (N=50 per vaccine group per timepoint) following 0+1 (at 12 months of age) or 1+1 (2 and 12 months of age) schedules of PCV10 or PCV13, using a multimer spectral flow cytometry approach. Blood samples were collected at 12 months of age (baseline) and at day 7 and day 28 post-vaccination.
A one or two dose schedule of either PCV induced robust serotype-specific B MEM responses at day 7 and day 28 for most serotypes. PCV13 generated earlier and higher B MEM responses than PCV10, while 1+1 schedules for either PCV produced higher B MEM responses than the 0+1 schedules at day 7. By day 28, these differences between the 0+1 and 1+1 schedules were no longer apparent. Notably, B MEM responses for serotypes 6B and 23F were detectable even in infants who did not achieve protective levels of serotype-specific IgG ≥0.35 µg/mL. PCV13 generated higher plasmablast and plasma cell responses by day 7, and higher cTfh responses by day 28, compared to PCV10.
These findings show that 1+1 schedules of PCV10 or PCV13 induce robust B MEM responses, with important implications for the evaluation of PCVs and understanding long-term protection.